Arrowhead Pharmaceuticals, Inc.
NASDAQArrowhead Pharmaceuticals enters late May with its strongest Street reception in months — yet options traders are quietly buying more protection than usual, creating a rare split between institutional conviction and tactical caution. The analyst story is the clearest signal this week. Morgan Stanley upgraded ARWR to Overweight on April 21, lifting its target to $100 from $78…
Snapshot as of 27 May 2026
Arrowhead Pharmaceuticals enters late May with its strongest Street reception in months — yet options traders are quietly buying more protection than usual, creating a rare split between institutional conviction and…
Arrowhead Pharmaceuticals heads into mid-May with a striking divergence: the Street is growing more constructive, yet short sellers are rebuilding positions at their fastest weekly pace in over a month. Short interest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARWR — free to start on ORTEX.
Sign up for free →Open ARWR on ORTEX